Today: 21 May 2026
P&G stock slides again after Wells Fargo cuts target — what investors watch next
6 January 2026
1 min read

P&G stock slides again after Wells Fargo cuts target — what investors watch next

NEW YORK, January 5, 2026, 21:15 EST — Market closed

  • Procter & Gamble shares fell about 1% on Monday, extending a five-session slide.
  • Wells Fargo cut its price target to $158 from $170 while keeping an Overweight rating.
  • Next catalysts include U.S. jobs data (Jan. 9) and P&G’s quarterly results (Jan. 22).

Procter & Gamble (PG.N) shares ended down about 1% on Monday at $140.37 after Wells Fargo cut its price target to $158 from $170 and kept an Overweight rating on the stock.

The move marked P&G’s fifth straight daily decline and left the stock about 22% below its 52-week high. Trading volume was about 12.1 million shares, above its 50-day average of 9.6 million.

The slide came on a strong day for the broader market, with the S&P 500 up 0.64% and the Dow up 1.23%. P&G also moved largely in step with parts of the defensive complex, with Johnson & Johnson and Colgate-Palmolive also lower.

Rate expectations are back in focus in early January, and that matters for steady cash-flow names such as P&G. “What keeps us awake at night is that inflation risk has resurfaced,” Julius Bendikas, European head of economics and dynamic asset allocation at Mercer, told Reuters. Reuters

Wells Fargo’s price-target cut brings its view to roughly 13% above Monday’s close, but P&G is still trading near the lower end of its 52-week range, with a low of $138.14. A price target is an analyst’s estimate of where a stock could trade over the next year; “Overweight” signals a preference versus peers in that coverage universe. marketwatch.com+1

Macro data in the coming sessions could move bond yields and shift the market’s appetite for defensive shares. The December U.S. employment report is due on January 9, followed by December CPI on January 13, according to the Labor Department’s release calendar.

The Federal Reserve’s next policy meeting is scheduled for January 27-28, a focal point for equity valuations as investors debate how quickly rate cuts can resume.

Company-specific attention turns to P&G’s quarterly results, where investors typically look for updates on pricing versus volumes, input-cost trends, and any changes to management’s outlook. The stock’s recent drift toward its 52-week low has also put technical support in view around the high-$130s.

But the set-up cuts both ways: if results show weaker demand, heavier promotions, or margin pressure, P&G risks breaking below support levels and slipping further out of favor as investors rotate toward faster-growing corners of the market.

P&G is scheduled to report fiscal second-quarter earnings on January 22 and host a conference call at 8:30 a.m. ET.

Stock Market Today

  • Stock Market Today: Key Insights for May 21 Trading
    May 20, 2026, 10:27 PM EDT. Stocks in the news and major brokerage calls shape market sentiment as traders prepare for May 21. This report provides a complete trade setup, highlighting critical market movements and strategies. Stay informed with the essential data before entering trades today.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Marvell (MRVL) stock lifts on Melius “buy” call, with CES CEO appearance next
Previous Story

Marvell (MRVL) stock lifts on Melius “buy” call, with CES CEO appearance next

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV
Next Story

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

Go toTop